Ezetimibe: Side Effects and Contraindications
Ezetimibe is one of the most widely prescribed cholesterol-lowering medicines in the UK after statins. It is generally well tolerated, but "well tolerated" does not mean free of risks. Our editorial team reviews how it works, what side effects are reported, who should avoid it and what interactions matter — including for physically active people.
How ezetimibe works
Ezetimibe lowers LDL cholesterol by blocking a transporter protein in the small intestine called Niemann–Pick C1-Like 1 (NPC1L1). This protein helps absorb cholesterol from food and from bile. When it is inhibited, less cholesterol reaches the liver, which responds by pulling more LDL out of the bloodstream.
On its own, ezetimibe typically reduces LDL cholesterol by around a fifth. Added to a statin, it gives a further reduction, which is why it is most often used in combination. The landmark IMPROVE-IT trial showed that adding ezetimibe to simvastatin after an acute coronary syndrome produced a modest additional reduction in cardiovascular events.
In the UK, ezetimibe is a prescription-only medicine. NICE technology appraisal guidance supports its use for primary hypercholesterolaemia when statins are not tolerated or are contraindicated, and in combination when a statin alone does not achieve adequate control. The licensed dose stated in the product information is 10 mg once daily.
Because its action is largely confined to the gut and it is processed differently from statins, ezetimibe has a different side-effect profile. That difference is often why doctors choose it for people who struggle with statins.
Common and less common side effects
In clinical trials, the overall rate of adverse effects with ezetimibe alone was similar to placebo. Nonetheless, the summary of product characteristics lists several reactions that patients should know about.
| Frequency (per product information) | Examples | Comment |
|---|---|---|
| Common | Abdominal pain, diarrhoea, wind, tiredness | Usually mild and often settle |
| Uncommon | Raised liver enzymes, muscle aches, nausea, indigestion, cough | More likely when combined with a statin |
| Not known (post-marketing) | Allergic reactions, rash, hepatitis, pancreatitis, gallstones, myopathy, rarely rhabdomyolysis | Seek medical help promptly if suspected |
Digestive symptoms are the most frequently reported. They tend to be mild and often improve over the first weeks of treatment. Persistent upper abdominal pain, particularly if severe or radiating to the back, should be assessed because pancreatitis and gallbladder problems have been reported rarely.
Muscle pain is a sensitive topic because statins are well known for it. With ezetimibe alone, true muscle toxicity appears to be rare, but cases of myopathy and rhabdomyolysis have been reported, mostly in people also taking a statin or fibrate. Unexplained muscle pain, weakness or dark urine require urgent medical review.
Allergic reactions, including rash, swelling of the face or throat and, very rarely, anaphylaxis, are possible with any medicine and require stopping the drug and seeking immediate help.
Who should not take ezetimibe
The main contraindication for ezetimibe alone is hypersensitivity to the active substance or any of the excipients. Additional restrictions apply when it is combined with a statin, because the statin brings its own contraindications.
- Hypersensitivity to ezetimibe or any ingredient, including lactose in some tablet formulations.
- Active liver disease or unexplained persistent rises in liver enzymes, when used together with a statin.
- Pregnancy and breastfeeding when combined with a statin; ezetimibe alone should only be used in pregnancy if clearly necessary.
- Moderate or severe hepatic impairment: not recommended, as drug exposure increases.
- Children: use is restricted to specific ages and specialist supervision.
People with rare inherited problems of galactose intolerance or glucose–galactose malabsorption should check the tablet ingredients, as many brands contain lactose.
Kidney impairment does not usually require dose adjustment for ezetimibe, but caution applies when combining it with statins in severe kidney disease, according to the product information.
Important drug interactions
Ezetimibe has relatively few interactions compared with many cardiovascular drugs because it is not metabolised by the cytochrome P450 system to a significant degree, as reviewed by Kosoglou and colleagues. Still, several combinations need attention.
Monitoring and practical points for active people
Typical monitoring involves a lipid profile several weeks after starting treatment and then periodically. When ezetimibe is combined with a statin, liver function tests are usually checked at baseline and during follow-up in line with statin guidance.
For people who lift weights or train intensively, interpreting creatine kinase and liver enzymes can be tricky because exercise alone raises them. Mention your training to the clinician and avoid strenuous sessions for a few days before blood tests, so that exercise-related changes are not mistaken for drug toxicity.
Ezetimibe is not a performance-enhancing drug and is not on the World Anti-Doping Agency Prohibited List. Its purpose is long-term cardiovascular protection, and it works best alongside diet, regular exercise and, where appropriate, statins.
Never stop a prescribed lipid-lowering medicine without discussing it with your doctor. If side effects are troublesome, alternatives exist, including different statin doses, newer agents such as bempedoic acid or PCSK9-targeting therapies, and dietary approaches.
Conclusions of the editorial team
Ezetimibe is a well-studied, generally well-tolerated cholesterol-lowering medicine that blocks intestinal cholesterol absorption. Most side effects are mild and digestive.
Rare but important risks include allergic reactions, liver enzyme rises, pancreatitis, gallbladder problems and muscle damage, the last mainly in combination with statins or fibrates.
Contraindications and interactions — notably with ciclosporin, bile acid sequestrants, fibrates and warfarin — should be reviewed by your prescriber and pharmacist.
You may also want to read our articles on reading a lipid profile, on citrus bergamot and cholesterol, and on how training affects liver blood tests.
References
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
- National Institute for Health and Care Excellence. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. Technology appraisal guidance TA385. London: NICE; 2016.
- Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–427.
- Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–494.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
